Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation

NCT01051388 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Cardio-cerebrovascular Disease

Interventions

DRUG: Low-dose PPI (Rabeprazole sodium)
DRUG: High-dose PPI (Rabeprazole sodium)
DRUG: Non-PPI (Gefarnate)

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Collaborators

[object Object]